Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Patrick S. Gentile"'
Autor:
Thomas M. Woodcock, Subash P. Sheth, Daniel M. Sullivan, Martin S. Blumenreich, Eliza J. Sherrill, Kim A. Lalley, Michael J. Kellihan, John T. Hamm, U. Geetha Joseph, Patrick S. Gentile, Janell Seeger
Publikováno v:
Cancer. 71:2828-2832
Background. Hydroxyurea is an S-phase specific drug. Constant exposure of tumor cells with a low S-phase fraction to the agent may result in improved cell kill. Because of its short half-life, a continuous intravenous infusion may result in better tu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::60d78ea911295c0a58deeef1eb0b9567
https://doi.org/10.1002/1097-0142(19930501)71:9<2828::aid-cncr2820710924>3.0.co
https://doi.org/10.1002/1097-0142(19930501)71:9<2828::aid-cncr2820710924>3.0.co
Publikováno v:
American journal of hematology. 38(1)
Leukopenia, thrombocytopenia, and anemia are important features of hairy cell leukemia (HCL). They are generally considered to be due to hypersplenism and to inadequate production by bone marrow which is heavily infiltrated by the neoplastic hairy ce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72a0739ccf44e2e6747e599689f685cb
https://pubmed.ncbi.nlm.nih.gov/1897512
https://pubmed.ncbi.nlm.nih.gov/1897512
Autor:
Stephen P. Richman, Joseph C. Allegra, Patrick S. Gentile, Martin S. Blumenreich, Thomas M. Woodcock, Thomas T. Kubota
Publikováno v:
Journal of Clinical Oncology. 1:247-250
Twenty-seven patients (25 males and 2 females) with histologically confirmed, unresectable, or metastatic non-small cell lung cancer were entered on a combination chemotherapy protocol including cisplatinum and vinblastine sulfate (DDP)(VLB). Patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0dc5672cd56d8eb8de814c9e4a4bcb9a
https://doi.org/10.1200/jco.1983.1.4.247
https://doi.org/10.1200/jco.1983.1.4.247
Publikováno v:
Critical Reviews in Oncology/Hematology. 7:71-87
Myelotoxicity remains a significant dose-limiting side effect of chemotherapy contributing to the morbidity and mortality of patients undergoing treatment for cancer. A number of different experimental approaches are being studied, both in the clinic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7edf1aab3725bce76391fd410f634846
https://doi.org/10.1016/s1040-8428(87)80015-x
https://doi.org/10.1016/s1040-8428(87)80015-x
Autor:
Barbara E. Epremian, Baby Jose, Eliza J. Sherrill, Stephen P. Richman, Martin S. Blumenreich, Thomas M. Woodcock, Patrick S. Gentile, George R. Barnes, Joseph C. Allegra, Thomas T. Kubota
Publikováno v:
Journal of Clinical Oncology. 5:1725-1730
Non-small-cell lung cancer (NSCLC) patients with locally advanced or metastatic measurable disease were given a combination of cisplatin, 200 mg/m2 divided in five daily doses, and simultaneously, vinblastine, 7.5 mg/m2 as a continuous intravenous (I
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::59e82a8e995ebd6d8c2b7e1f8dd91b9f
https://doi.org/10.1200/jco.1987.5.11.1725
https://doi.org/10.1200/jco.1987.5.11.1725
Publikováno v:
Cancer. 62:711-715
Recognition of disseminated adenocarcinomas potentially responsive to current treatment programs is an important objective in the management of cancer patients. Metastatic adenocarcinoma of the prostate gland is a malignant entity which often can be
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ccd65a7c768a95c0ce5566dc9c3c0f22
https://doi.org/10.1002/1097-0142(19880815)62:4<711::aid-cncr2820620411>3.0.co
https://doi.org/10.1002/1097-0142(19880815)62:4<711::aid-cncr2820620411>3.0.co
Autor:
Thomas T. Kubota, Barbara E. Epremian, Thomas M. Woodcock, Joseph C. Allegra, Patrick S. Gentile, Martin S. Blumenreich, Eliza J. Sherrill, Stephen P. Richman
Publikováno v:
Cancer Investigation. 6:371-375
We carried out a phase I trial with chlorambucil. Thirty patients with advanced cancer were entered in six dose levels: 36, 48, 60, 84, 108, and 144 mg/m2. The drug was given in six divided oral doses every 6 hours and the regimen was repeated every
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f51f86854e5ae1c995e82c62e7cc25e
https://doi.org/10.3109/07357908809080064
https://doi.org/10.3109/07357908809080064
Publikováno v:
Blood. 65:91-99
The regulation of myelopoiesis was evaluated in B6D2F1 mice inoculated with Friend virus complex (spleen focus-forming virus plus helper virus) or helper virus alone by analyzing acidic isoferritin (AIF) and lactoferrin (LF) interactions with target
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::37f7104a66c627be48bc63c4c4ee34e0
https://doi.org/10.1182/blood.v65.1.91.91
https://doi.org/10.1182/blood.v65.1.91.91
Autor:
Martin S. Blumenreich, Thomas M. Woodcock, Mariesa Jones, Stephen P. Richman, Thomas T. Kubota, Joseph C. Allegra, Patrick S. Gentile
Publikováno v:
Cancer. 55:1118-1122
A study was conducted to determine if cisplatin (CDDP) can be given at higher doses than usual, utilizing aggressive supportive measures. Twelve patients were entered into three dose levels of CDDP: level I, 180 mg/m2 given as a short infusion; level
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a31f751efe259557713a9c8cc76cd1f9
https://doi.org/10.1002/1097-0142(19850301)55:5<1118::aid-cncr2820550529>3.0.co
https://doi.org/10.1002/1097-0142(19850301)55:5<1118::aid-cncr2820550529>3.0.co
Autor:
Mariesa Jones, Stephen P. Richman, Patrick S. Gentile, Joseph C. Allegra, Martin S. Blumenreich, Thomas T. Kubota, Thomas M. Woodcock
Publikováno v:
Cancer. 56:256-258
Eighteen patients with advanced malignancies refractory to other forms of treatment were given dactinomycin (Act D) as continuous intravenous infusions. Their median age was 51 years (range, 36-67); their median performance status was 50 (range, 40-9
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e5092d1ce56cd49bc08380dbbf60785e
https://doi.org/10.1002/1097-0142(19850715)56:2<256::aid-cncr2820560208>3.0.co
https://doi.org/10.1002/1097-0142(19850715)56:2<256::aid-cncr2820560208>3.0.co